HighVista Strategies’s ProPhase Labs PRPH Stock Holding History

HighVista Strategies’s Portfolio PRPH Stock Details PRPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,026	Closed	-$105K	–	103
2021 Q3	$105K	Buy	+2,026	New	+$121K	0.07%	92

Other funds holding PRPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AWE

Avidian Wealth Enterprises Houston, Texas $3.62B AUM 24.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's PRPH Position: Q4 2021 in Review

HighVista Strategies sold out of ProPhase Labs (PRPH) in Q4 2021, closing a stake of 2,026 shares — an estimated $105K sold.

HighVista Strategies first reported a position in PRPH in Q3 2021 and held it in 1 quarter. The position peaked at $105K in Q3 2021. 25 funds tracked by Wall St. Rank hold PRPH as of Q4 2021.

HighVista Strategies reported no remaining ProPhase Labs position as of Q4 2021 after selling out during the quarter.
HighVista Strategies sold 2,026 ProPhase Labs shares in Q4 2021, an estimated $105K.
HighVista Strategies first reported a position in ProPhase Labs in Q3 2021 and held it in 1 quarter.
HighVista Strategies's ProPhase Labs position peaked at $105K in Q3 2021.
25 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.